Innovating the next generation of immunological therapeutics

Grants and Awards

The TLA immunotherapy has received awards and competitive funding from the following sources:


2010: Swedish Governmental Agency for Innovation Systems (Phase I/II Clinical Trial on TLA for Inflammatory Bowel Disease): SEK 5 Million.

2012: European Union Eureka EUROSTARS (Phase I/II Clinical Trial on TLA for Acute Respiratory Distress Syndrome): SEK 5 Million.

2013: Swedish Research Council (Phase I/II Clinical Trial on paediatric Inflammatory Bowel Disease, Primary Sclerosing Cholangitis, Alcoholic Hepatitis, Rheumatoid Arthritis, Multiple Sclerosis and Amyotrophic Lateral Sclerosis): SEK 5 Million.

2013: Swedish Governmental Agency for Innovation Systems (Phase II Clinical Trial on Inflammatory Bowel Disease): SEK 5 Million.

Awards and Recognition 

2012: Universal Biotech Innovation Prize, Paris, France

2013: Dagens Medicin's Athena Prize, Stockholm, Sweden 

2014: Innovative Sweden, Swedish Institute: Selected as a model innovation to highlight Swedish innovativeness globally.